New Data Presented from Oncopeptides' Pivotal Phase 2 HORIZON Trial Evaluating Melflufen in Relapsed/Refractory Multiple Myeloma at 24th EHA Congress - Seite 4

About Oncopeptides 
Oncopeptides is a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological cancers. The company is focusing on the development of the lead product candidate melflufen, a novel lipophilic peptide conjugated alkylator, belonging to a new class of drugs called Peptidase Enhanced Cytotoxics (PEnC). Melflufen is in development as a new treatment for the hematological cancer multiple myeloma, including the Phase 2 pivotal trial HORIZON currently underway and a global confirmatory Phase 3 trial (OCEAN) continuing enrollment. Oncopeptides' headquarters is located in Stockholm, Sweden, and the company is listed in the Mid Cap segment on Nasdaq Stockholm with the ticker ONCO. 

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/oncopeptides-ab/r/new-data-presented-from-oncopeptides--pivotal-phase-2-horizon-trial-evaluating-melflufen-in-relapsed,c2841457

The following files are available for download:

https://mb.cision.com/Main/15404/2841457/1063287.pdf	Press release - Oncopeptides New Data from the study HORIZON
https://news.cision.com/oncopeptides-ab/i/interim-efficacy,c2642132	Interim Efficacy
https://news.cision.com/oncopeptides-ab/i/tabell---totala-responsen,c2 ...	tabell - totala response